Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27523486 | 1.00 | SLC6A3 (0.60) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL5730962 | 1.00 | SLC6A3 (0.60) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL2989416 | 1.00 | SLC6A3 (0.60) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL8696563 | 1.00 | SLC6A3 (0.60) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL6944840 | 1.00 | SLC6A3 (0.60) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL6944834 | 1.00 | SLC6A3 (0.60) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL2989418 | 1.00 | SLC6A3 (0.60) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL6574577 | 1.00 | SLC6A3 (0.60) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL6573763 | 1.00 | SLC6A3 (0.60) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL6152741 | 0.87 | SLC6A3 (0.65) | SLC6A3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007028770-A1 | MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS FOR NEUROPROTECTION IN PATIENTS SUFFERING FROM AN ADVANCED STAGE OF A MENTAL DISEASE | NEUROSEARCH A/S (DK) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007028769-A1 | MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITOR FOR NEUROPROTECTION | NEUROSEARCH A/S (DK) | 2007-03-15 | — | — | WO | disclosed |
| US-20050277664-A1 | Monoamine neurotransmitter re-uptake inhibitor for the inhibition of beta-amyloid generation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277664-A1 | Monoamine neurotransmitter re-uptake inhibitor for the inhibition of beta-amyloid generation | SLC6A2, SLC18A2, SLC18A3 | SLC6A3 7/4885SLC6A2 1/4885SLC6A4 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.